Mereo BioPharma Group plc
MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Naviā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.38
Price-8.87%
-$0.04
1Y
Price
Market Cap
$61.375m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$500k
-
1y CAGR-33.3%
3y CAGR-50.0%
5y CAGREarnings
-$41.508m
+4.0%
1y CAGR-4.2%
3y CAGR-89.5%
5y CAGREPS
-$0.27
+6.9%
1y CAGR+48.0%
3y CAGR-47.4%
5y CAGRBook Value
$46.598m
$53.602m
Assets$7.004m
Liabilities$397k
DebtDebt to Assets
0.7%
-
Debt to EBITDAFree Cash Flow
-$33.029m
+1.5%
1y CAGR+0.6%
3y CAGR-131.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company